• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Sana Biotechnology Inc.

    5/11/26 4:17:05 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SANA alert in real time by email
    S-8 1 d134015ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on May 11, 2026

    Registration No. 333-   

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Sana Biotechnology, Inc.

    (Exact name of Registrant as specified in its charter)

     

     

     

    Delaware   83-1381173

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

    188 East Blaine Street, Suite 350

    Seattle, Washington 98102

      98102
    (Address of Principal Executive Offices)   (Zip Code)

     

     

    2021 Incentive Award Plan

    (Full Title of the Plan)

     

     

    Aaron M. Grossman

    Executive Vice President, Chief Legal Officer

    Sana Biotechnology, Inc.

    188 East Blaine Street, Suite 350

    Seattle, Washington 98102

    (206) 701-7914

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

    Tony Jeffries

    Jennifer Knapp

    Phillip McGill

    Wilson Sonsini Goodrich & Rosati, Professional Corporation

    650 Page Mill Road

    Palo Alto, CA 94304

    (650) 493-9300

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    EXPLANATORY NOTE

    Sana Biotechnology, Inc. (the “Registrant”) is filing this Registration Statement on Form S-8 (this “Registration Statement”) for the purpose of registering an additional 13,336,582 shares of common stock under the Registrant’s 2021 Incentive Award Plan, as amended (the “2021 Plan”), for which registration statements of the Registrant on Form S-8 (File Nos. 333-287088, 333-279219, 333-271728, 333-264846, and 333-252862) are effective (the “Prior Registration Statements”), pursuant to the provisions of the 2021 Plan that provide for an automatic annual increase in the number of shares of common stock reserved for issuance thereunder. This Registration Statement relates to securities of the same class as those to which the Prior Registration Statements relate and is submitted in accordance with General Instruction E to Form S-8 regarding Registration of Additional Securities. Pursuant to General Instruction E to Form S-8, the contents of the Prior Registration Statements are incorporated herein by reference and made part of this Registration Statement, except as amended hereby.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3.

    Incorporation of Documents by Reference.

    The Registrant hereby incorporates by reference into this Registration Statement the following documents filed by it with the Securities and Exchange Commission (the “SEC”):

     

      (a)

    the Registrant’s Annual Report on Form 10-K (File No. 001-39941) for the fiscal year ended December 31, 2025, filed with the SEC on March 3, 2026 (the “Annual Report”);

     

      (b)

    all other reports filed pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), since the end of the fiscal year covered by the Annual Report (other than the portions of these documents not deemed to be filed); and

     

      (c)

    the description of the Registrant’s common stock contained in the Registrant’s Registration Statement on Form 8-A (File No. 001-39941) filed with the Commission on January 25, 2021, pursuant to Section  12(b) of the Exchange Act, as updated and superseded by the description of the Registrant’s common stock contained in Exhibit 4.3 to the Annual Report, including any amendments or reports filed for the purpose of updating such description.

    All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such Current Report that relate to such items) subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with the rules of the SEC shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Item 8.

    Exhibits.

    The exhibits to this Registration Statement are listed below and are incorporated herein by reference.


    EXHIBIT INDEX

     

            

    Incorporated by Reference

    Exhibit

    Number

      

    Description

     

    Schedule

    Form

     

    File Number

     

    Exhibit

     

    Filing Date

    4.1

       Form of Common Stock Certificate.   S-1/A   333-252061   4.2   January 28, 2021

    5.1*

       Opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation.        

    23.1*

       Consent of Wilson Sonsini Goodrich & Rosati, Professional Corporation (included in Exhibit 5.1).        

    23.2*

       Consent of Independent Registered Public Accounting Firm.        

    24.1*

       Power of Attorney (included on the signature page of this Registration Statement).        

    99.1(a)

       2021 Incentive Award Plan.   S-8   333-279219   99.1(a)   May 8, 2024

    99.1(b)

       First Amendment to 2021 Incentive Award Plan, dated as of December 8, 2021.   10-K   001-39941   10.4(b)   March 16, 2022

    99.1(c)

       Form of Stock Option Grant Notice and Stock Option Agreement under the 2021 Incentive Award Plan.   S-1/A   333-252061   10.4(b)   January 28, 2021

    99.1(d)

       Form of Stock Option Grant Notice and Stock Option Agreement under the 2021 Incentive Award Plan.   10-K   001-39941   10.4(d)   March 16, 2022

    99.1(e)

       Form of Restricted Stock Award Grant Notice and Restricted Stock Award Agreement under the 2021 Incentive Award Plan.   S-1/A   333-252061   10.4(c)   January 28, 2021

    99.1(f)

       Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2021 Incentive Award Plan.   S-1/A   333-252061   10.4(d)   January 28, 2021

    107.1*

       Filing Fee Table.        

     

    *

    Filed herewith.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Seattle, State of Washington, on May 11, 2026.

     

    SANA BIOTECHNOLOGY, INC.

    By:

     

    /s/ Steven D. Harr, M.D.

     

    Steven D. Harr, M.D.

     

    President and Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Steven D. Harr, M.D. and Brian Piper, and each of them, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement and any and all additional registration statements pursuant to Rule 462(b) of the Securities Act of 1933, as amended, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact and agents full power and authority to do and perform each and every act in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or either of them or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

     

    Signature    Title   Date

    /s/ Steven D. Harr, M.D.

    Steven D. Harr, M.D.

       President, Chief Executive Officer, and Director (Principal Executive Officer)   May 11, 2026

    /s/ Brian Piper

    Brian Piper

       Executive Vice President, Chief Financial Officer (Principal Financial Officer)   May 11, 2026

    /s/ Susan D. Wyrick

    Susan D. Wyrick

       Senior Vice President, Finance and Accounting (Principal Accounting Officer)   May 11, 2026

    /s/ Hans E. Bishop

    Hans E. Bishop

       Chairman of the Board   May 11, 2026

    /s/ Joshua H. Bilenker, M.D.

    Joshua H. Bilenker, M.D.

       Director   May 11, 2026

    /s/ Richard Mulligan, Ph.D.

    Richard Mulligan, Ph.D.

       Director   May 11, 2026

    /s/ Robert Nelsen

    Robert Nelsen

       Director   May 11, 2026


    /s/ Alise S. Reicin, M.D.

    Alise S. Reicin, M.D.

       Director   May 11, 2026

    /s/ Robert L. Rosiello

    Robert L. Rosiello

       Director   May 11, 2026

    /s/ Michelle Seitz, CFA

    Michelle Seitz

       Director   May 11, 2026

    /s/ Patrick Y. Yang, Ph.D.

    Patrick Y. Yang, Ph.D.

       Director   May 11, 2026
    Get the next $SANA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SANA

    DatePrice TargetRatingAnalyst
    5/11/2026$16.00Buy
    Rodman & Renshaw
    9/24/2025$5.00Outperform
    Wedbush
    7/3/2025$12.00Overweight
    Morgan Stanley
    3/18/2025$5.00Mkt Perform → Mkt Outperform
    Citizens JMP
    3/14/2025$7.00Buy
    Jefferies
    1/8/2025Hold → Buy
    TD Cowen
    11/5/2024Mkt Outperform → Mkt Perform
    JMP Securities
    6/26/2024$16.00Buy
    Rodman & Renshaw
    More analyst ratings

    $SANA
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Sana Biotechnology Inc.

    SCHEDULE 13G - Sana Biotechnology, Inc. (0001770121) (Subject)

    5/21/26 9:12:55 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 8-K filed by Sana Biotechnology Inc.

    8-K - Sana Biotechnology, Inc. (0001770121) (Filer)

    5/15/26 4:06:25 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 filed by Sana Biotechnology Inc.

    S-8 - Sana Biotechnology, Inc. (0001770121) (Filer)

    5/11/26 4:17:05 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SANA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rodman & Renshaw initiated coverage on Sana Biotechnology with a new price target

    Rodman & Renshaw initiated coverage of Sana Biotechnology with a rating of Buy and set a new price target of $16.00

    5/11/26 8:07:57 AM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Wedbush initiated coverage on Sana Biotechnology with a new price target

    Wedbush initiated coverage of Sana Biotechnology with a rating of Outperform and set a new price target of $5.00

    9/24/25 7:58:10 AM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Morgan Stanley resumed coverage on Sana Biotechnology with a new price target

    Morgan Stanley resumed coverage of Sana Biotechnology with a rating of Overweight and set a new price target of $12.00

    7/3/25 7:51:55 AM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SANA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Nelsen Robert bought $9,999,996 worth of shares (1,818,181 units at $5.50) (SEC Form 4)

    4 - Sana Biotechnology, Inc. (0001770121) (Issuer)

    2/12/24 5:46:20 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Crandell Keith bought $9,999,996 worth of shares (1,818,181 units at $5.50) (SEC Form 4)

    4 - Sana Biotechnology, Inc. (0001770121) (Issuer)

    2/12/24 5:43:56 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Arch Venture Fund X, L.P. bought $9,999,996 worth of shares (1,818,181 units at $5.50) (SEC Form 4)

    4 - Sana Biotechnology, Inc. (0001770121) (Issuer)

    2/12/24 5:43:09 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SANA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Bishop Hans Edgar

    4 - Sana Biotechnology, Inc. (0001770121) (Issuer)

    4/8/26 4:16:24 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Patel Dhavalkumar Dhirajlal

    3 - Sana Biotechnology, Inc. (0001770121) (Issuer)

    3/27/26 4:15:24 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President & CEO Harr Steve covered exercise/tax liability with 24,345 shares and converted options into 91,666 shares, increasing direct ownership by 0.85% to 7,944,251 units (SEC Form 4)

    4 - Sana Biotechnology, Inc. (0001770121) (Issuer)

    3/10/26 4:16:12 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SANA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum

    USA News Group News CommentaryIssued on behalf of Avaí Bio, Inc.As the broader cell and gene therapy complex posts record quarterly revenue and advances toward accelerated approval pathways, a Nevada-based longevity joint venture has just cleared a manufacturing-stage gate on its α-Klotho anti-aging program.NEW YORK, May 28, 2026 /CNW/ -- Cell and gene therapy has crossed a meaningful inflection in 2026. Vertex Pharmaceuticals reported Q1 product revenue of $2.99 billion, with newer non-CF franchises CASGEVY and JOURNAVX contributing more than 25% of year-over-year growth. Alnylam Pharmaceuticals delivered its first-ever $1 billion product revenue quarter. Beam Therapeutics presented updated

    5/28/26 9:15:00 AM ET
    $ALNY
    $BEAM
    $SANA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Sana Biotechnology to Present at June 2026 Investor Conferences

    SEATTLE, May 27, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in June. The presentations will feature a business overview and update. Sana will present at the Jefferies Global Healthcare Conference at 9:20 a.m. ET on Wednesday, June 3, 2026.Sana will present at the Goldman Sachs 47th Annual Global Healthcare Conference at 4:00 p.m. ET on Tuesday, June 9, 2026. The webcasts will be accessible on the Investor Relations page of Sana's website at https://sana.com/. A replay of each presentation will be availab

    5/27/26 4:05:00 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility

    SEATTLE , May 15, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has sold an aggregate of 21,607,878 shares of the company's common stock through its at-the-market ("ATM") facility established through TD Securities (USA) LLC for net proceeds of approximately $69 million. The investment, including participation based on interest received from RA Capital Management, combined with the previously announced unrelated $25 million investment from the Mayo Clinic, brings the total capital raised since the end of the first quarter of 2026 to approximately $94 million and exten

    5/15/26 9:00:00 AM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SANA
    Leadership Updates

    Live Leadership Updates

    View All

    Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates

    Announced strategic collaboration with Mayo Clinic, focused on improving care in type 1 diabetes and accelerating development of SC451 Continued progress toward starting SC451 Phase 1 trial later this year, including manufacturing readiness, non-clinical testing, and clinical trial preparation Announced positive clinical results at 14 months from ongoing clinical trial transplanting UP421 without any immunosuppression into a patient with type 1 diabetes, showing ongoing survival and function Continued progress toward starting clinical study for SG293 in non-Hodgkin lymphoma later this year, including manufacturing readiness, non-clinical testing, and clinical trial preparation Will prese

    5/11/26 4:05:00 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sana Biotechnology Appoints Brian Piper as Executive Vice President, Chief Financial Officer

    SEATTLE, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced the appointment of Brian Piper as Executive Vice President, Chief Financial Officer. Mr. Piper brings to Sana a breadth of biopharmaceutical financial and operational expertise with over 25 years of experience in various positions in the industry. Mr. Piper was most recently CFO of Scorpion Therapeutics and its post-acquisition spin-off, Antares Therapeutics. "I am thrilled to welcome Brian to Sana and to our leadership team," said Steve Harr, President and Chief Executive Officer of Sana. "He brings deep exper

    2/17/26 9:00:00 AM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ajit Singh Appointed CEO of Harbinger Health and CEO-Partner of Flagship Pioneering

    Stephen Hahn to Transition to CEO Emeritus and Special Advisor and remain on Harbinger's board CAMBRIDGE, Mass., Aug. 11, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Harbinger Health, a biotechnology company pioneering the detection of early cancer, today announced the appointment of Ajit Singh, Ph.D. as CEO-Partner of Flagship and the new CEO of Harbinger.  Dr. Singh, a veteran of the diagnostics industry, will also continue as a Harbinger board member, a role he has held since 2024. Dr. Singh succeeds Stephen Hahn, M.D., who will transition from his role as CEO and remain closely involved with the company as CEO Emeritus and Special Advisor. He will co

    8/11/25 12:00:00 PM ET
    $FHTX
    $MRNA
    $SANA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $SANA
    Financials

    Live finance-specific insights

    View All

    Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

    Following FDA input, Seres submitted Phase 2 study protocol to FDA for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat hematological malignancies Seres engaging with multiple parties regarding various deal structures, including potential business development and partnerships, intended to secure capital and other resources to enable the clinical advancement of SER-155 and additional live biotherapeutic product candidates Seres received the $25 million installment payment, as expected, from Nestlé Health Science in July 2025 Conference call at 8:30 a.m. ET today CAM

    8/6/25 7:00:00 AM ET
    $MCRB
    $SANA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

    First-in-Human Study Provides Evidence that Sana's Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression Results Demonstrate HIP-Engineered Primary Pancreatic Islet Cells Avoid Immune Detection, Function, and Persist after Intramuscular Transplantation in First Treated Patient with Type 1 Diabetes Function and Persistence of Pancreatic Islets Were Detectable by Production of Consistent Levels of Circulating C-Peptide, a Marker of Insulin Production, and Increased C-Peptide Levels with a Mixed Meal Tolerance Test (MMTT) MRI Shows Signals Consistent with Graft Survival 28 Days after Transplantation Study Contin

    1/7/25 4:05:00 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SANA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

    SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

    11/14/24 5:12:32 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

    SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

    11/14/24 6:00:14 AM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

    SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

    11/12/24 4:52:24 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care